Semaglutide tied to quality of life improvements vs. placebo in type 2 diabetes, CKD

Compared with placebo, semaglutide was associated with improved quality of life outcomes for patients with type 2 diabetes and chronic kidney disease. Study data were presented at the European Renal Association Congress in Glasgow, Scotland.

Raccontata dahealio.com